MedTrace Logo

CD64 and Antibiotics in Human Sepsis

NCT02922998 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2024-12-10

No results posted yet for this study

Summary

The purpose of the study is to find out whether CD64 expression on neutrophils measured by a new bedside test (LeukoDx) within 30 minutes is associated with effective antibiotic therapy in critically ill adult patients at risk of sepsis.

Conditions

  • Antibiotic Resistant Infection
  • Critical Illness
  • SIRS
  • Sepsis

Sponsors & Collaborators

  • University of Ulm

    lead OTHER

Principal Investigators

  • Manfred Weiss, MD · Department of Anaesthesiology, University Hospital Ulm; Ulm, Germany 89075

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2019-12-31
Completion
2021-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02922998 on ClinicalTrials.gov